Previous 10 | Next 10 |
Becton, Dickinson, and Company ( NYSE: BDX ) announced Wednesday that the FDA issued Emergency Use Authorization (EUA) for a combination test that can detect COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) infections simultaneously. The test, designed for use in the company...
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test PR Newswire Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J. , ...
Summary William von Mueffling's 13F portfolio value increased this quarter from $11.04B to $11.81B. Cantillon added CDW Corp and increased BlackRock, Interactive Brokers, Entegris, and Armstrong World Industries during the quarter. The portfolio continues to be very concentrated wit...
Summary DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued. Growth and value investors may find respective equities interesting. I use DXCM and EMBC as a lens to view developments in ...
Summary Becton, Dickinson and Company is a leading player in the medical technology and life sciences industries, with a focus on both inpatient and outpatient settings. Becton, Dickinson in fiscal Q1 2023 reported a 3% growth in revenue to $4.59 billion and exceeded EPS expectations ($...
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery PR Newswire New BD Rhapsody™ HT Xpress System and Other Innovations to be Unveiled at AGBT, Enhancing an End-To-End Single-Cell Multiomics Offering FRANKL...
Becton, Dickinson's ( NYSE: BDX ) Q4 2022 financial results, which saw a beat on the top and bottom lines and a 2023 guidance lift, was met with approval by Street analysts. Evercore ISI's Vijay Kumar, who has an outperform rating on the stock, boosted his price target to $2...
Becton, Dickinson and Company (BDX) Q1 2023 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Francesca DeMartino – Senior Vice President and Head-Investor Relations Tom Polen – Chairman, Chief Executive Officer and President Chris...
The following slide deck was published by Becton, Dickinson and Company in conjunction with their 2023 Q1 earnings call. For further details see: Becton, Dickinson and Company 2023 Q1 - Results - Earnings Call Presentation
Becton, Dickinson press release ( NYSE: BDX ): Q1 Non-GAAP EPS of $2.98 beats by $0.30 . Revenue of $4.6B (-2.5% Y/Y) beats by $10M . Company raises full-year revenue and adjusted EPS guidance: The company now expects fiscal year 2023 revenues to be in the range of...
News, Short Squeeze, Breakout and More Instantly...
Becton Dickinson and Company Company Name:
BDX Stock Symbol:
NYSE Market:
Becton Dickinson and Company Website:
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials PR Newswire Company Committed to Support Global Health and Customers BD Taking all Available Measures to Mitigate Supplier Issue FRANKLIN LAKES, N.J. , July 10 , 2024...